Nicholas Zaorsky, Vice Chair of Education; Professor with Tenure at University Hospitals, shared a post by JAMA Oncology, on X, adding:
“For men with prostate cancer treated with radiation therapy, what is the ideal duration of hormone therapy? Intermediate risk: <6 months High risk: ~12 months (For most) The longer the hormones, the less death from prostate cancer, but more death from heart attack, stroke, etc.”
Quoting JAMA Oncology‘s post:
“Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group.”
Title: Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis
Authors: Nicholas G. Zaorsky, Yilun Sun, Abdenour Nabid, Almudena Zapatero, Michel Bolla, David Joseph, Philippe Maingon, Araceli Guerrero, Ana Alvarez Gonzalez, Carmen Gonzalez San-Segundo, Maria Ángeles Cabeza Rodríguez, Josep Maria Sole, Agustí Pedro Olivé, Allison Steigler, Luis Souhami, Nathalie Carrier, John G. Armstrong, Charles Gillham, Thomas M. Pisansky, Matthew Schipper, Howard M. Sandler, Jason A. Efstathiou, Colleen Lawton, Theo M. de Reijke, Gerhardt Attard, Soumyajit Roy, Scott C. Morgan, Shawn Malone, William A. Hall, Paul L. Nguyen, Jonathan E. Shoag, Randy A. Vince Jr, Adam Calaway, Jorge A. Garcia, Pedro C. Barata, Prateek Mendiratta, Jason R. Brown, Luca Valle, Matthew Rettig, Robert T. Dess, William C. Jackson, Ting Martin, Angela Y. Jia, Michael Steinberg, Tahmineh Romero, Amar U. Kishan, Daniel E. Spratt
More posts featuring Nicholas Zaorsky on OncoDaily.